Type 2 diabetes mellitus and cancer: The role of pharmacotherapy

Journal of Clinical Oncology

Volumn 34, Issue 35, 2016, Pages 4261-4269

  Shlomai, Gadi ^a,b   Neel, Brian ^a   LeRoith, Derek ^a   Gallagher, Emily Jane ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLUCOCORTICOID; HORMONE; INCRETIN; INSULIN DERIVATIVE; INSULIN GROWTH FACTOR 1 RECEPTOR INHIBITOR; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METFORMIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN INHIBITOR; PROTEIN KINASE B INHIBITOR; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

CANCER INCIDENCE; CANCER MORTALITY; CLINICAL STUDY; DRUG THERAPY; GLUCOSE HOMEOSTASIS; HUMAN; HYPERGLYCEMIA; INSULIN RELEASE; INSULIN RESISTANCE; MALIGNANT NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; COMPLICATION; DIABETES MELLITUS, TYPE 2; INCIDENCE; MORTALITY; NEOPLASMS; RISK FACTOR;

ANTINEOPLASTIC AGENTS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN RESISTANCE; NEOPLASMS; RISK FACTORS;

EID: 85002932905     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.67.4044     Document Type: Review

References (92)

1. Alberti KG: Screening and diagnosis of prediabetes: Where are we headed? Diabetes Obes Metab 9(Suppl 1):12-16, 2007
2. Tsilidis KK, Kasimis JC, Lopez DS, et al: Type 2 diabetes and cancer: Umbrella review of metaanalyses of observational studies. BMJ 350:g7607, 2015
3. Barone BB, Yeh HC, Snyder CF, et al: Longterm all-cause mortality in cancer patients with preexisting diabetes mellitus: A systematic review and meta-analysis. JAMA 300:2754-2764, 2008
4. Campbell PT, Newton CC, Patel AV, et al: Diabetes and cause-specific mortality in a prospective cohort of one million U. S. adults. Diabetes Care 35:1835-1844, 2012
5. Harding JL, Shaw JE, Peeters A, et al: Cancer risk among people with type 1 and type 2 diabetes: Disentangling true associations, detection bias, and reverse causation. Diabetes Care 38:264-270, 2015
6. Gordon-Dseagu VL, Shelton N, Mindell JS: Epidemiological evidence of a relationship between type-1 diabetes mellitus and cancer: a review of the existing literature. Int J Cancer 132:501-508, 2013
7. Carstensen B, Read SH, Friis S, et al: Cancer incidence in persons with type 1 diabetes: A fivecountry study of 9, 000 cancers in type 1 diabetic individuals. Diabetologia 59:980-988, 2016
8. Giovannucci E, Harlan DM, Archer MC, et al: Diabetes and cancer: A consensus report. Diabetes Care 33:1674-1685, 2010
9. Singh S, Earle CC, Bae SJ, et al: Incidence of diabetes in colorectal cancer survivors. J Natl Cancer Inst 108:djv402, 2016
10. Lipscombe LL, Goodwin PJ, Zinman B, et al: Increased prevalence of prior breast cancer in women with newly diagnosed diabetes. Breast Cancer Res Treat 98:303-309, 2006
11. Onitilo AA, Stankowski RV, Berg RL, et al: Breast cancer incidence before and after diagnosis of type 2 diabetes mellitus in women: Increased risk in the prediabetes phase. Eur J Cancer Prev 23:76-83, 2014
12. Ahern TP, Hankinson SE, Willett WC, et al: Plasma C-peptide, mammographic breast density, and risk of invasive breast cancer. Cancer Epidemiol Biomarkers Prev 22:1786-1796, 2013
13. Jenab M, Riboli E, Cleveland RJ, et al: Serum C-peptide, IGFBP-1 and IGFBP-2 and risk of colon and rectal cancers in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer 121:368-376, 2007
14. Crowe FL, Key TJ, Allen NE, et al: A crosssectional analysis of the associations between adult height, BMI and serum concentrations of IGF-I and IGFBP-1-2 and -3 in the European Prospective Investigation into Cancer and Nutrition (EPIC). Ann Hum Biol 38:194-202, 2011
15. Yu H, Rohan T: Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92:1472-1489, 2000
16. Belfiore A, Frasca F, Pandini G, et al: Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30:586-623, 2009
17. Mulligan AM, O'Malley FP, Ennis M, et al: Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Res Treat 106:39-47, 2007
18. Harrington SC, Weroha SJ, Reynolds C, et al: Quantifying insulin receptor isoform expression in FFPE breast tumors. Growth Horm IGF Res 22:108-115, 2012
19. Decensi A, Puntoni M, Goodwin P, et al: Metformin and cancer risk in diabetic patients: A systematic review and meta-analysis. Cancer Prev Res (Phila) 3:1451-1461, 2010
20. Gandini S, Puntoni M, Heckman-Stoddard BM, et al: Metformin and cancer risk and mortality: A systematic review and meta-analysis taking into account biases and confounders. Cancer Prev Res (Phila) 7:867-885, 2014
21. Col NF, Ochs L, Springmann V, et al: Metformin and breast cancer risk: A meta-analysis and critical literature review. Breast Cancer Res Treat 135:639-646, 2012
22. Zhou G, Myers R, Li Y, et al: Role of AMPactivated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174, 2001
23. Han K, Pintilie M, Lipscombe LL, et al: Association between metformin use and mortality after cervical cancer in older womenwith diabetes. Cancer Epidemiol Biomarkers Prev 25:507-512, 2016
24. Margel D, Urbach DR, Lipscombe LL, et al: Metformin use and all-cause and prostate cancerspecific mortality among men with diabetes. J Clin Oncol 31:3069-3075, 2013
25. Lega IC, Shah PS, Margel D, et al: The effect of metformin on mortality following cancer among patients with diabetes. Cancer Epidemiol Biomarkers Prev 23:1974-1984, 2014
26. El-Mir MY, Nogueira V, Fontaine E, et al: Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 275:223-228, 2000
27. Fendt SM, Bell EL, Keibler MA, et al: Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res 73:4429-4438, 2013
28. Salani B, Marini C, Rio AD, et al: Metformin impairs glucose consumption and survival in Calu-1 cells by direct inhibition of hexokinase-II. Sci Rep 3:2070, 2013
29. Hirsch HA, Iliopoulos D, Struhl K: Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci USA 110:972-977, 2013
30. Núñez M, Medina V, Cricco G, et al: Glibenclamide inhibits cell growth by inducing G0/G1 arrest in the human breast cancer cell line MDA-MB-231. BMC Pharmacol Toxicol 14:6, 2013
31. Tuccori M, Wu JW, Yin H, et al: The use of glyburide compared with other sulfonylureas and the risk of cancer in patients with type 2 diabetes. Diabetes Care 38:2083-2089, 2015
32. Yang X, So WY, Ma RC, et al: Use of sulphonylurea and cancer in type 2 diabetes-The Hong Kong Diabetes Registry. Diabetes Res Clin Pract 90:343-351, 2010
33. Girnun GD, Chen L, Silvaggi J, et al: Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin Cancer Res 14:6478-6486, 2008
34. Mueller E, Smith M, Sarraf P, et al: Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer. Proc Natl Acad Sci USA 97:10990-10995, 2000
35. Monami M, Dicembrini I, Mannucci E: Thiazolidinediones and cancer: Results of a meta-analysis of randomized clinical trials. Acta Diabetol 51:91-101, 2014
36. Azoulay L, Yin H, Filion KB, et al: The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: Nested case-control study. BMJ 344:e3645, 2012
37. Lewis JD, Ferrara A, Peng T, et al: Risk of bladder cancer among diabetic patients treated with pioglitazone: Interim report of a longitudinal cohort study. Diabetes Care 34:916-922, 2011
38. Lewis JD, Habel LA, Quesenberry CP, et al: Pioglitazone use and risk of bladder cancer and other common cancers in persons with diabetes. JAMA 314:265-277, 2015
39. Piccinni C, Motola D, Marchesini G, et al: Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 34:1369-1371, 2011
40. Rosol TJ: On-target effects of GLP-1 receptor agonists on thyroid C-cells in rats and mice. Toxicol Pathol 41:303-309, 2013
41. Koehler JA, Baggio LL, Yusta B, et al: GLP-1R agonists promote normal and neoplastic intestinal growth through mechanisms requiring Fgf7. Cell Metab 21:379-391, 2015
42. Gokhale M, Buse JB, Gray CL, et al: Dipeptidylpeptidase-4 inhibitors and pancreatic cancer: A cohort study. Diabetes Obes Metab 16:1247-1256, 2014
43. Scirica BM, Bhatt DL, Braunwald E, et al: Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317-1326, 2013
44. Singh S, Chang HY, Richards TM, et al: Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: A population-based matched casecontrol study. JAMA Intern Med 173:534-539, 2013
45. Scafoglio C, Hirayama BA, Kepe V, et al: Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci USA 112:E4111-E4119, 2015
46. Saito T, Okada S, Yamada E, et al: Effect of dapagliflozin on colon cancer cell [Rapid Communication]. Endocr J 62:1133-1137, 2015
47. Lin HW, Tseng CH: A review on the relationship between SGLT2 inhibitors and cancer. Int J Endocrinol 2014:719578, 2014
48. Reilly TP, Graziano MJ, Janovitz EB, et al: Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus. Diabetes Ther 5:73-96, 2014
49. De Jonghe S, Proctor J, Vinken P, et al: Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin. Chem Biol Interact 224:1-12, 2014
50. Gallagher EJ, LeRoith D: Obesity and diabetes: The increased risk of cancer and cancerrelated mortality. Physiol Rev 95:727-748, 2015
51. Bordeleau L, Yakubovich N, Dagenais GR, et al: The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. Diabetes Care 37:1360-1366, 2014
52. Stammberger I, Essermeant L: Insulin glargine: A reevaluation of rodent carcinogenicity findings. Int J Toxicol 31:137-142, 2012
53. Ferris HA, Kahn CR: New mechanisms of glucocorticoid-induced insulin resistance: Make no bones about it. J Clin Invest 122:3854-3857, 2012
54. Hwang JL, Weiss RE: Steroid-induced diabetes: A clinical and molecular approach to understanding and treatment. Diabetes Metab Res Rev 30:96-102, 2014
55. Ma H, Zhang T, Shen H, et al: The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapy. Br J Clin Pharmacol 77:917-928, 2014
56. Ariaans G, De Jong S, Gietema JA, et al: Cancer-drug induced insulin resistance: Innocent bystander or unusual suspect. Cancer Treat Rev 41:376-384, 2015
57. Rachdi L, Balcazar N, Osorio-Duque F, et al: Disruption of Tsc2 in pancreatic beta cells induces beta cell mass expansion and improved glucose tolerance in a TORC1-dependent manner. Proc Natl Acad Sci USA 105:9250-9255, 2008
58. Le May C, Chu K, Hu M, et al: Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc Natl Acad Sci USA 103:9232-9237, 2006
59. Xu B, Lovre D, Mauvais-Jarvis F: Effect of selective estrogen receptor modulators on metabolic homeostasis. Biochimie 124:92-97, 2016
60. Yu IC, Lin HY, Sparks JD, et al: Androgen receptor roles in insulin resistance and obesity in males: The linkage of androgen-deprivation therapy to metabolic syndrome. Diabetes 63:3180-3188, 2014
61. Tsilidis KK, Capothanassi D, Allen NE, et al: Metformin does not affect cancer risk: A cohort study in the U. K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial. Diabetes Care 37:2522-2532, 2014
62. Pollak M: Overcoming drug development bottlenecks with repurposing: Repurposing biguanides to target energy metabolism for cancer treatment. Nat Med 20:591-593, 2014
63. Suissa S, Azoulay L: Metformin and the risk of cancer: Time-related biases in observational studies. Diabetes Care 35:2665-2673, 2012
64. Kowall B, Stang A, Rathmann W, et al: No reduced risk of overall, colorectal, lung, breast, and prostate cancer with metformin therapy in diabetic patients: Database analyses from Germany and the UK. Pharmacoepidemiol Drug Saf 24:865-874, 2015
65. Lega IC, Austin PC, Gruneir A, et al: Association between metformin therapy and mortality after breast cancer: A population-based study. Diabetes Care 36:3018-3026, 2013
66. ClinicalTrials.gov: Home-ClinicalTrials.gov. https://clinicaltrials.gov
67. Goodwin PJ, Stambolic V, Lemieux J, et al: Evaluation of metformin in early breast cancer: A modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 126:215-220, 2011
68. Rangwala SM, Lazar MA: Peroxisome proliferator-activated receptor gamma in diabetes and metabolism. Trends Pharmacol Sci 25:331-336, 2004
69. Burstein HJ, Demetri GD, Mueller E, et al: Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: A phase II study. Breast Cancer Res Treat 79:391-397, 2003
70. Yee LD, Williams N, Wen P, et al: Pilot study of rosiglitazone therapy in women with breast cancer: Effects of short-term therapy on tumor tissue and serum markers. Clin Cancer Res 13:246-252, 2007
71. Baggio LL, Drucker DJ: Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131-2157, 2007
72. Mizutani S, Sumi S, Narita O, et al: Purification and properties of human placental dipeptidyl peptidase IV. Nippon Sanka Fujinka Gakkai Zasshi 37:769-775, 1985
73. Elashoff M, Matveyenko AV, Gier B, et al: Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology 141:150-156, 2011
74. Koehler JA, Kain T, Drucker DJ: Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells. Endocrinology 152:3362-3372, 2011
75. Derogar M, Hull MA, Kant P, et al: Increased risk of colorectal cancer after obesity surgery. Ann Surg 258:983-988, 2013
76. Bronsveld HK, Ter Braak B, Karlstad Ø, et al: Treatment with insulin (analogues) and breast cancer risk in diabetics: A systematic review and metaanalysis of in vitro, animal and human evidence. Breast Cancer Res 17:100, 2015
77. Wu JW, Filion KB, Azoulay L, et al: Effect of long-acting insulin analogs on the risk of cancer: A systematic review of observational studies. Diabetes Care 39:486-494, 2016
78. Pasello G, Urso L, Conte P, et al: Effects of sulfonylureas on tumor growth: A review of the literature. Oncologist 18:1118-1125, 2013
79. Ptaszynska A, Cohen SM, Messing EM, et al: Assessing bladder cancer risk in type 2 diabetes clinical trials: The dapagliflozin drug development program as a 'case study'. Diabetes Ther 6:357-375, 2015
80. Pufall MA: Glucocorticoids and cancer. Adv Exp Med Biol 872:315-333, 2015
81. Hickish T, Astras G, Thomas P, et al: Glucose intolerance during adjuvant chemotherapy for breast cancer. J Natl Cancer Inst 101:537, 2009
82. Ellis ME, Weiss RB, Korzun AH, et al: Hyperglycemic complications associated with adjuvant chemotherapy of breast cancer. A cancer and leukemia group B (CALGB) study. Am J Clin Oncol 9:533-536, 1986
83. Wu W, Merriman K, Nabaah A, et al: The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma. Br J Cancer 111:628-636, 2014
84. Bosco C, Crawley D, Adolfsson J, et al: Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: A metaanalysis. PLoS One 10:e0117344, 2015
85. Laaksonen DE, Niskanen L, Punnonen K, et al: Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 27:1036-1041, 2004
86. Ben-Shmuel S, Scheinman EJ, Rashed R, et al: Ovariectomy is associated with metabolic impairments and enhanced mammary tumor growth in MKR mice. J Endocrinol 227:143-151, 2015
87. Nuutila P, Knuuti MJ, Maki M, et al: Gender and insulin sensitivity in the heart and in skeletal muscles. Studies using positron emission tomography. Diabetes 44:31-36, 1995
88. Lipscombe LL, Fischer HD, Yun L, et al: Association between tamoxifen treatment and diabetes: A population-based study. Cancer 118:2615-2622, 2012
89. Geuna E, Roda D, Rafii S, et al: Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on phase I clinical trials. Br J Cancer 113:1541-1547, 2015
90. Vergès B, Cariou B: mTOR inhibitors and diabetes. Diabetes Res Clin Pract 110:101-108, 2015
91. Busaidy NL, Farooki A, Dowlati A, et al: Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol 30:2919-2928, 2012
92. Beckwith H, Yee D: Minireview: Were the IGF signaling inhibitors all bad? Mol Endocrinol 29:1549-1557, 2015